Composition for the treatment of arthritis containing a dibenzo-p-dioxin derivative as the active ingredient
Disclosed is a composition for treating arthritis containing a dibenzo-p-dioxin derivative as an active ingredient. This dibenzo-p-dioxin derivative is very effective in inhibiting NF-kB and AP-1 activity, alleviates the symptoms of degenerative arthritis and rheumatoid arthritis without irritating the skin or causing side effects, and can continue to exhibit improvement effects for a considerable period of time after discontinuation of treatment. Additionally, when the dibenzo-p-dioxin derivative is contained in liposomes, the composition of the invention exhibits much greater effects on treating arthritis by absorption through skin, and thus is useful for the treatment of degenerative arthritis and rheumatoid arthritis.
1. A method of treating degenerative arthritis or rheumatoid arthritis in a mammal, the method comprising:
applying a medicament to a skin of the mammal in need of such treatment, the medicament comprising a pharmaceutically acceptable carrier and at least one composition using three or more compounds represented by Formulas 1 to 7 and 10:
wherein the at least one composition is selected from the group consisting of:
a first composition comprising 60% of the compound of Formula 2 (R═H), 25% of the compound of Formula 3 (R═H), and 15% of the compound of Formula 4 (R═H) with respect to the total weight thereof,
a second composition comprising 70% of the compound of Formula 4 (R═H), 8% of the compound of Formula 5 (R═H), and 22% of the compound of Formula 6 (R═H) with respect to the total weight thereof,
a third composition comprising 10% of the compound of Formula 4 (R═H), 80% of the compound of Formula 10 (R═H), and 10% of the compound of Formula 7 (R═H) with respect to the total weight thereof, and
a fourth composition comprising 3% of the compound of Formula 1 (R═H), 37% of the compound of Formula 2 (R═H), 4% of the compound of Formula 3 (R═H), 6% of the compound of Formula 4 (R═H), 25% of the compound of Formula 5 (R═H), and 25% of the compound of Formula 6 (R═H) with respect to the total weight thereof.
2. The method according to claim 1 , wherein the total weight of the at least one composition ranges from 0.2 to 2.0 wt % of the total weight of the medicament.
3. The method according to claim 1 , wherein the total weight of the at least one composition ranges from 0.5 to 1.5 wt % of the total weight of the medicament.
4. The method according to claim 1 , wherein the medicament is in a form selected from the group consisting of an ointment, a lotion, a cream, a gel, a skin emulsion, a skin suspension, a patch, and a spray.
5. The method according to claim 1 , wherein the medicament further comprises a liposome, wherein the at least one composition is contained in the liposome.
6. The method according to claim 5 , wherein the liposome comprises multi-lamella vesicles.
7. The method according to claim 5 , wherein the liposome comprises unilamella vesicles.
8. The method according to claim 1 , wherein the compounds inhibit NF-kB activity or AP-1 activity in cells of the mammal.